Male dyspepsia with mildly diarrheal IBS
Conditions
Interventions
Famotidine-preceding group: Famotidine(20mg/day)is administered to study patient for 4 weeks. After 4 weeks famotidine(20mg/day)+ramosetron(5ug/day)are administered for 4 weeks.
Famotidine-preceding
Sponsors
Hyogo College of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patient to whom the subscale score of pain, discomfort of regurgitation is 3 or more and score of diarrhea is 2 or more in Izumo Scale 2.Duration of dyspepsia is 4 weeks or more 3.Male 4.From 20 years old to less or equal to 70 year old 5.Patient who obtained written informed consent
Exclusion criteria
Exclusion criteria: 1.Patient who has a history of hypersensitivity 2.Patient who has organic illness such as gastroduodenal ulcer, gastric cancer, intestinal cancer or imflammatory bowel disease 3.Patient with chronic constipation or constipated IBS 4.Patient who is currently receiving H2RA, PPI or drugs for IBS 5.Patient who has renal disorder 6.Patient who has cardiovascular diseases 7.Patient who has hepatic disorder 8.Patient who is pregnant nursing mom 9.Patient wit whome the physicina-in-charge considered inappropriate as a subject of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in total score of gastrointestinal symptom questionnaire, Izumo Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| *Changes in subscale scores and summary scores of health related QOL SF-8 *Chnages in subscale scores of Izumo Scale *Patient preference of treatment(famotidine alone or combination of famotidine and ramosetron) at the end of trial | — |
Countries
Japan
Contacts
Public ContactHiroto Miwa
Hyogo College of Medicine Division of Upper Gastroenterology, Department of Internal Medicine
Outcome results
None listed